Investing-News.Com
Information for Investors

CYTRX CP, (CYTR) Stock Ratings - Investing-News.Com
 

 Home   Market News   Analysis   Commentary   Education   Tools   Weekly Report 

Internet Search   Stock Search
   

 

CYTRX CP, (CYTR) Stock Rating Learn More

Our Overall Rating on CytRx Corporation,  CYTR is STRONG BUY
StockPickReport.Com research suggests CYTR's price will move significantly higher than the "open price" the day this rating was initiated.

This analysis is based on short-term stochastic and "relative strength" indicators.

Both stochastic and "relative strength" indicators point to a move up.

Investors, traders, and other market participants may find this a good opportunity to buy CYTR, "buy calls", or "sell puts".

This may also be an opportunity to raise targets and stop/losses to allow for potential gains.

Trading volume seems to be falling and CYTR's closing price moved down during the week before this rating was initiated.

Our STRONG BUY Rating on CYTR was issued on 03/25/08

CYTRX CP Technical Rating



Ratings Provided by Stock-Letter-Daily.Com

Rate Any Stock
(enter symbol and click)

Stock Rating Definitions

Stock Ratings Home

Sponsored Links:

Software Forces CYTRX CP Investors To Buy Low and Sell High The Position Cost Averaging Stock Investing Systems helps LONG-TERM investors in CYTRX CP buy low and sell high every time guaranteed. Click Here To Learn More

We Give Precision Entry & Exit Points on CYTRX CP. This software is specially designed to give precision entry and exit points on CYTRX CP, or any other stock you choose.
Click Here to learn how to take control of your trading.

How To Know When CYTRX CP Beats The Street. New Software Offers "One-Click" Stock Picks. The StockPickerRT will pick stocks for you every trading day based on earnings, volume & momentum. Maybe even CYTRX CP, if they make the cut.
Click Here & Learn To
Pick Winners In An Uncertain Market



Related Searches: stock trading tool  investing market revealed secret stock  merck stock quote  stock market quote research 

Research Home


Article Search


Advanced Search

StreetInsider Alerts

Latest Headlines

CytRx Unveils Clinical Development Plan for Pipeline Assets (Business Wire)

CYTRX CORP Financials (EDGAR Online Financials)

CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (EDGAR Online)

INNO-406 Demonstrates Positive Clinical Responses in Phase 1 Trial in Patients with Chronic Myeloid Leukemia (Business Wire)

CytRx Corporation Announces 2008 Third Quarter Financial Results (Business Wire)

CYTRX CORP Files SEC form 10-Q, Quarterly Report (EDGAR Online)

CytRx Corporation to Present at the Rodman & Renshaw Annual Healthcare Conference (Business Wire)

CytRx Corporation's 45% Owned Affiliate RXi Pharmaceuticals Obtains an Exclusive Worldwide License to Technology for the Oral Delivery of RNAi Therapeutics from the University of Massachusetts Medical School (Business Wire)

CytRx Corporation to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference (Business Wire)

Video Interview: Steven Kriegsman, Director, President and CEO, CytRx Corporation (GlobeNewswire)

  Place Our Content On Your Site!  rss Powered By The Investing System Network
© 2006 Investing-News.Com, All Rights Reserved.